Which prior treatments must adult patients with advanced renal cell carcinoma have progressed on or after for Welireg (belzutifan) to be indicated?

Welireg (belzutifan) is indicated for adults with advanced renal cell carcinoma whose disease has progressed on or after treatment with both a programmed death receptor-1 (PD-1)/programmed death ligand (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).